BAL PHARMA LIMITED

Corporate Office
+91 80 4137 9500
info@balpharma.com
5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India.

Date: August 12, 2026

To
Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

Symbol: BALPHARMA

To
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400001

Scrip Code: 524824

Sub: Unaudited Standalone and Consolidated Financial Results for the First Quarter ended on 30th June, 2026 along with the Limited Review Report.

Dear Sir/Madam,

We herewith enclosed the Unaudited Standalone and Consolidated Financial Results of the Company for the First quarter ended on 30th June, 2026 (Q1/2026-27) as approved by the Board of Directors together with the Limited Review Report as submitted by the Statutory Auditors.

The meeting commenced at 04.45 PM and concluded at 05.15 PM on Wednesday, August 12, 2026.

Please takes this intimation on your records

Thanking You.

For Bal Pharma Limited

Shreepada ML

Digitally signed by Shreepada ML
DN: cn=Shreepada ML, o, ou, email=sribhat111@gmail.com, c=US
Date: 2026.08.12 17:19:48 +05'30'

BAL PHARMA LTD
CIN L85110KA1987PLC008368
BENGALURU

Shreepada ML
Company Secretary and Compliance officer
ICSI M No : A66681

Corporate Office
+91 80 4137 9500
info@balpharma.com
5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India.

Date: August 12, 2026

To
Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

Symbol: BALPHARMA

To
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400001

Scrip Code: 524824

Sub: Non applicability of statement of Deviation/ Variation
Ref: Regulation 32(1) of SEBI (LODR) Regulations ,2015.

Dear Sir/Madam,

With reference to the above cited subject and reference, we would like to clarify that as the Company has neither raised any funds through public issue, rights issue, preferential issue, QIP etc nor has any proceeds of the earlier issues outstanding for utilization for the quarter ended 30.06.2026, filing of statement of deviation/variation in utilization of funds raised is not applicable to the Company, for the above said quarter.

Please takes this intimation on your records

Thanking You.

For Bal Pharma Limited

BAL PHARMA LTD. CIN L85110KA1987PLC008368 BENGALURU

Shailesh Siroya
Managing Director
DIN : 00048109

BAL PHARMA LIMITED

Corporate Office
+91 80 4137 9500
info@balpharma.com
5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India.

Date: August 12, 2026

To
Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

Symbol: BALPHARMA

To
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400001

Scrip Code: 524824

Sub: Declaration of Unmodified Opinion on Audited Financial Results for the quarter and financial year ending 30.06.2026

Dear Sir/Madam,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that the statutory auditors of the Company M/s. SSJNB & Co, Chartered Accountants, having membership # 00139768 have issued their limited review report with Unmodified opinion on audited Standalone and Consolidated Financial results of the Company, for the quarter and financial year ended 30th June 2026.

Please takes this intimation on your records

Thanking You.

For Bal Pharma Limited

BAL PHARMA LTD
CIN L85110KA1987PLC008368
BENGALURU

Shailesh Siroya
Managing Director
DIN : 00048109

Independent Auditor's review report on the Quarterly and year to date unaudited standalone financial results of Bal Pharma Limited pursuant to the Regulation 33 of SEBI (Listing obligations and Disclosures Requirements) Regulations, 2015, as amended

To the Board of Directors of Bal Pharma Limited

We have reviewed the accompanying statement of unaudited standalone financial results of **Bal Pharma Limited** ("the Company") for the quarter ended 30th June 2026 and the year to date from 1st April 2026 to 30th June 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and which has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting "("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent auditor of the Entity"* issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A Review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we have become aware of all significant matters that may be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that caused us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and disclosure Requirements) Regulations 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s. **S S J N B & Co**
Chartered Accountants
Firm registration number: 013976S

DHANPAL I SAKARIA
Digitally signed by DHANPAL I SAKARIA
Date: 2026.08.12 17:46:08 +05'30'

Dhanpal I Sakaria
Partner
Membership No: 213666
UDIN: 26213666AAQBBY4418

Place: Bengaluru
Date: 12 August 2026

BAL PHARMA LIMITED

CIN: L85110KA1987PLC008368

Regd.Office: 21-22 Bommasandra Industrial Area,Anekal Taluq,Bangalore 560 099

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2026

in Rs. Lakhs

Sl No.	Particulars	Quarter Ended			Year ended
		30-Jun-2026 Unaudited	31-Mar.2026 Audited	30-Jun-2025 Unaudited	31-Mar-2026 Audited
	Income				
I	Revenue from operations	8,842.73	8,391.76	6,563.51	31,079.70
II	Other income	45.71	-21.82	74.11	200.29
III	**Total Income - (I)+(II)**	**8,888.44**	**8,369.95**	**6,637.62**	**31,279.99**
IV	**Expenses**				
	a) Cost of materials consumed	4,847.25	4,113.65	3,602.85	16,096.74
	b) Purchase of Stock-in-trade	294.39	144.06	397.39	912.94
	c) Changes in inventories of finished goods, Stock-in-trade and work-in-progress	-25.24	-419.43	-652.18	-1,224.63
	d) Employees benefits expenses	1,692.64	1,791.82	1,466.83	6,592.40
	e) Finance costs	446.56	405.26	405.19	1,681.02
	f) Depreciation and amortization expense	278.22	304.18	251.90	1,105.90
	g) Other expenses	1,238.52	1,699.00	1,133.31	5,479.10
	Total Expense - (IV)	**8,772.34**	**8,038.54**	**6,605.30**	**30,643.48**
V	**Profit before Exceptional item and Tax (III-IV)**	**116.10**	**331.41**	**32.31**	**636.51**
VI	Exceptional items				
VII	Profit/ (Loss) before Tax (V-VI)	116.10	331.41	32.31	636.51
VIII	Less: Tax Expense				
	Current tax		-		-
	Excess/Short provision of tax written back		-		-
	Tax adjustments relating to previous year		-		-
	Deferred tax charge/ (credit)		-38.61		-38.61
		-	(38.61)	-	(38.61)
IX	**Net Profit for the period**	**116.10**	**370.02**	**32.31**	**675.12**
X	**Other Comprehensive Income(OCI)**				
	- Items that may not be reclassified to Profit or loss		43.37		43.37
	- Income tax relating to items that will not be reclassified to profit or loss		-	-	-
	Tax	**0.00**	**43.37**	**0.00**	**43.38**
XI	**Total Comprehensive income for the period (IX+X)**	**116.10**	**413.39**	**32.31**	**718.50**
XII	Paid up Equity Share Capital (Face value ₹ 10 per share)	1,592.09	1,592.09	1,592.09	1,592.09
XIII	Other Equity		8,817.82		8,817.82
XIV	Earnings per share (Face value of ₹ 10 each)				
	Basic - in ₹	0.73	2.60	0.20	4.51
	Diluted - in ₹	0.73	2.60	0.20	4.51

Notes:

1 The above standalone financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th August 2026

2 The standalone financial results has been prepared in accordance with the Companies(Indian Accounting Standards) Rules, 2015(IND AS), prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recoganised accounting practices and policies to the extent applicable.

3 The Company has only one reportable segment namely 'Pharmaceuticals'.

4 Previous period figures have been regrouped/rearranged whereever considered necessary to conform to the period presentation.

For Bal Pharma Limited

SHAILESH SIROYA

Digitally signed by SHAILESH SIROYA
DN: c=IN, o=Personal,
2.5.4.20=84ab941967c90d592e2ff174fc0c3d1e2a28f54cc3b61e26f9cd3fff67d54c4a, postalCode=560020, st=Karnataka,
serialNumber=0f3b0eb66c935e3f2972d9a58c18f3254e937f84f1fce82bf0fe2fb061000bc5, cn=SHAILESH SIROYA
Date: 2026.08.12 17:46:52 +05'30'

Shailesh Siroya
Managing Director
DIN : 00048109

Date : 12/08/2026
Place : Bangalore

S S J N B & Co

Chartered Accountants

Landline: 080-4977 7951 / 52 / 53 / 54

Email: office@ssjnb.in

Independent Auditor's review report on the Quarterly and year to date unaudited consolidated financial results of Bal Pharma Limited pursuant to the Regulation 33 of SEBI (Listing obligations and Disclosures Requirements) Regulations, 2015, as amended

To the Board of Directors of Bal Pharma Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **BAL PHARMA LIMITED ("the Parent")** and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit/(loss) after tax and total comprehensive income/loss for the quarter ended 30th June, 2026 and the year to date from 1st April 2026 to 30th June, 2026 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015, as amended.

2. This consolidated statement, which is the responsibility of the Parent's Management and which has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the consolidated statement based on our review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The statement includes the financial results of following entities:

Lifezen Health Care Private Limited	Subsidiary
Balance Clinics LLP	Subsidiary
Bal Research Foundation	Subsidiary
Aurum Research & Analytical Solutions Private Limited	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We reviewed the financial results of aforementioned subsidiary companies included in the consolidated audited financial results, whose financial results reflect total income (before consolidation adjustments) of ₹. 38.23 lakhs for period ended June 30, 2026 and total net loss after tax (before consolidation adjustments) of ₹. 2.33 lakhs for the period ended June 30, 2026.

For M/s**. S S J N B & Co**
Chartered Accountants
Firm registration number: 013976S

DHANPAL I SAKARIA
Digitally signed by DHANPAL I SAKARIA
Date: 2026.08.12 17:48:35 +05'30'

Dhanpal I Sakaria
Partner
Membership No: 213666
UDIN: 26213666YAKIWG7924

Place: Bengaluru
Date: 12 August 2026

BAL PHARMA LIMITED

CIN: L85110KA1987PLC008368

Regd.Office: 21-22 Bommasandra Industrial Area,Anekal Taluq,Bangalore 560 099

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2026

in Rs. Lakhs

Sl No.	Particulars	Quarter Ended			Year Ended
		30-Jun-2026 Unaudited	31-Mar.2026 Audited	30-Jun-2025 Unaudited	31 March 2026 Audited
	Income				
I	Revenue from operations	8,861.61	8,407.57	6,587.09	31,166.13
II	Other income	43.82	-23.65	72.22	192.78
III	**Total Income - (I)+(II)**	**8,905.43**	**8,383.92**	**6,659.31**	**31,358.91**
IV	**Expenses**				
	a) Cost of materials consumed	4,847.25	4,113.65	3,602.85	16,096.74
	b) Purchase of Stock-in-trade	290.73	142.03	398.47	922.66
	c) Changes in inventories of finished goods, Stock-in-trade and work-in-progress	-22.78	-422.96	(647.06)	-1,222.89
	d) Employees benefits expenses	1,706.38	1,806.55	1,480.37	6,646.48
	e) Finance costs	446.59	405.55	405.34	1,681.76
	f) Depreciation and amortization expense	278.25	305.80	252.04	1,107.93
	g) Other expenses	1,245.23	1,711.56	1,146.45	5,532.84
	Total Expense - (IV)	**8,791.66**	**8,062.19**	**6,638.46**	**30,765.53**
V	**Profit before Exceptional item and Tax (III-IV)**	**113.77**	**321.74**	**20.85**	**593.38**
VI	Exceptional items	-	-	-	-
VII	Profit/ (Loss) before Tax (V-VI)	113.77	321.74	20.85	593.38
VIII	Less: Tax Expense				
	Current tax	-			-
	Excess/Short provision of tax written back	-			-
	Tax adjustments relating to previous year	-			-
	Deferred tax charge/ (credit)	-	-38.62		-38.62
		-	(38.62)	-	(38.62)
IX	**Net Profit for the period**	**113.77**	**360.36**	**20.85**	**632.00**
	Profit / (Loss) attributable to :				
	- Equity holders of the parent company	112.35	359.35	20.06	628.36
	- Non controlling interest	1.42	1.01	0.79	3.65
X	**Other Comprehensive Income(OCI)**				
	- Items that may not be reclassified to Profit or loss	-	43.85		43.85
	- Income tax relating to items that will not be reclassified to profit or loss	-		-	-
	Income Tax	**-**	**43.85**	**-**	**43.85**
XI	**Total Comprehensive income for the period (IX+X)**	**113.77**	**404.21**	**20.85**	**675.85**
	Profit / (Loss) attributable to :				
	Equity holders of the parent company	112.35	359.35	20.06	628.36
	Non controlling interest	1.42	1.01	0.79	3.65
XII	Paid up Equity Share Capital (Face value ₹ 10 per share)	1,592.09	1,592.09	1,592.09	1,592.09
XIII	Other Equity		6,630.65		6,630.65
XIV	Earnings per share (Face value of ₹ 10 each)				
	Basic - in ₹	0.71	2.26	0.13	3.95
	Diluted - in ₹	0.71	2.26	0.13	3.95

Notes:

1 The above consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th August 2026

2 The consolidated financial results has been prepared in accordance with the Companies(Indian Accounting Standards) Rules, 2015(IND AS), prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recoganised accounting practices and policies to the extent applicable.The audited consilidated financial results relate to Balpharma Limited, its subsidiaries (together constitute 'the group'). Joint venture and Associates and are preparedby applying IND AS 110 - " Consolidate Financial Statements ", and IND AS 28 - "Investment s in Associates & Joint ventures".

3 Previous period figures have been regrouped/rearranged whereever considered necessary to conform to the period presentation.

4 The Company has only one reportable segment namely 'Pharmaceuticals'.

For Bal Pharma Limited

SHAILESH SIROYA

Digitally signed by SHAILESH SIROYA
DN: c=IN, o=Personal,
2.5.4.20=84ab941967c90d592e2ff174fc0c3d1e2a28f54cc3b61e26f9cd3fff67d54c4a, postalCode=560020, st=Karnataka,
serialNumber=0f3b0eb66c935e3f2972d9a58c18f3254e937f84f1fce82bf0fe2fb061000bc5, cn=SHAILESH SIROYA
Date: 2026.08.12 17:45:36 +05'30'

Shailesh Siroya
Managing Director
DIN : 00048109

Date : 12/08/2026
Place : Bangalore